Le Lézard
Classified in: Health, Business
Subjects: LIC, ACC

ZINZINO AB (PUBL): Zinzino changes Certified Adviser to Carnegie Investment Bank AB (publ)


GOTHENBURG, Sweden, Nov. 30, 2023 /PRNewswire/ -- Zinzino announces today that it is changing Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).

Zinzino has entered into an agreement with Carnegie Investment Bank AB (publ) regarding the service as Certified Adviser. Carnegie Investment Bank AB (publ) will take over as Certified Adviser on 30 November 2023. Until then, Erik Penser Bank AB will continue to act as Certified Adviser for the company.

For more information please contact :
Fredrik Nielsen CFO Zinzino +46 707 900 174, email: [email protected]

Images for free publication: 
[email protected]

Certified Adviser: Carnegie Investment Bank AB  (publ)

The following files are available for download:

https://mb.cision.com/Public/10976/3885209/9ec0b10627c4dbbd.pdf

Press Release Zinzino CA - Carnegie EN


These press releases may also interest you

at 20:14
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP agilon health, inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors to Contact the Firm (AGL)
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. Announces Launch of its INSTI® HCV Antibody Test for Professional Use in Australia
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines' ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...

More news about Health...


News published on and distributed by: